Avecho Biotechnology Limited

ASX:AVE Stock Report

Market Cap: AU$6.3m

Avecho Biotechnology Valuation

Is AVE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AVE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AVE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AVE's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AVE?

Key metric: As AVE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AVE. This is calculated by dividing AVE's market cap by their current revenue.
What is AVE's PS Ratio?
PS Ratio18.7x
SalesAU$339.30k
Market CapAU$6.34m

Price to Sales Ratio vs Peers

How does AVE's PS Ratio compare to its peers?

The above table shows the PS ratio for AVE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.8x
CGB Cann Global
9.7xn/aAU$5.4m
BOD Bod Science
1.3xn/aAU$4.3m
EPN Epsilon Healthcare
1xn/aAU$7.2m
RGT Argent BioPharma
15.2xn/aAU$13.6m
AVE Avecho Biotechnology
18.7xn/aAU$6.3m

Price-To-Sales vs Peers: AVE is expensive based on its Price-To-Sales Ratio (18.7x) compared to the peer average (5.8x).

Price to Sales Ratio vs Industry

How does AVE's PS Ratio compare vs other companies in the AU Pharmaceuticals Industry?

16 CompaniesPrice / SalesEstimated GrowthMarket Cap
MYX Mayne Pharma Group
0.9x11.3%US$236.25m
PBP Probiotec
1.1x6.7%US$160.13m
VLS Vita Life Sciences
1.5xn/aUS$76.10m
VIT Vitura Health
0.5xn/aUS$37.04m
AVE 18.7xIndustry Avg. 4.9xNo. of Companies16PS01224364860+
16 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: AVE is expensive based on its Price-To-Sales Ratio (18.7x) compared to the Australian Pharmaceuticals industry average (4.9x).

Price to Sales Ratio vs Fair Ratio

What is AVE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AVE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio18.7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate AVE's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Neuren Pharmaceuticals

AU$1.6b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

NEU

AU$12.36

7D

-26.0%

1Y

-17.0%

Little Green Pharma

AU$39.2m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

LGP

AU$0.14

7D

0%

1Y

10.2%

Medical Developments International

AU$47.3m

Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.

MVP

AU$0.42

7D

-5.6%

1Y

-46.8%